ABOUT BRIACELL

BriaCell Investor Presentation – Spring 2021 BriaCell Fact Sheet – Spring 2021

Dedicated to enhance the lives of women with breast cancer with limited therapy options, BriaCell Therapeutics Corp.’s (NASDAQ: BCTX, BCTXW) (TSX-V:BCT) mission has been to develop novel immunotherapies to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering the potential for higher levels of safety and efficacy than chemotherapy and may also prevent cancer recurrence.

Bria-IMT™: Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show impressive potential for treating breast cancer patients. BriaCell’s lead product candidate, Bria-IMT™, has been shown to activate the immune system in advanced breast cancer patients and destroy cancer cells. BriaCell maintains rights for Bria-IMT™.

Bria-IMT™ Monotherapy: In a preliminary Phase I clinical study in advanced breast cancer patients who had failed multiple treatments, Bria-IMT™ therapy was able to significantly reduced tumor size, without serious side effects. Importantly, regression of breast cancer has been observed in other sites including the lung and even the brain -a very difficult site to treat. Impressively, the median lifespan of the patients was substantially longer than anticipated in these advanced breast cancer patients.

BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer (ClinicalTrials.gov as NCT03066947).

Collaboration with Incyte Corporation: BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with BriaCell’s drug candidates in advanced breast cancer patients.

BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a combination with the immunotherapy development candidates retifanlimab (INCMGA00012), an anti-PD-1 antibody, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (both provided by Incyte). The combination study is listed in ClinicalTrials.gov as NCT03328026.

Bria-OTS™*: BriaCell is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for the treatment for advanced stage breast cancer.

In November 2020, BriaCell announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI, Center for Cancer Research), part of the National Institutes of Health, to investigate the mechanism of action of novel off-the-shelf personalized therapeutics for cancer.

Small Molecule Program: BriaCell’s small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.

* The continuation and completion of these studies depends on BriaCell securing adequate capital to execute these studies.

BREAST CANCER: FACTS & STATISTICS

  • According to the report published by the American Cancer Society in 2021, approximately 608,570 Americans are expected to die of cancer in 2021 (approximately 1,670 deaths per day), making cancer the second leading cause of death in the US, exceeded only by heart disease.
  • As of January 2021, the number of women in the USA with a history of invasive breast cancer is estimated at 3.1 million (excluding the estimated 284,200 new cases in 2021). The number is expected to increase by 12% to 4 million in 2024. Approximately 30% of breast cancers occur in women younger than 50 and 44% occur in women older than 65.
  • According to the facts and figures released by the American Cancer Society in 2021, 281,550 women, and 2,650 men are expected to be diagnosed with invasive breast cancer in 2021 in the US alone. Breast cancer is the most frequently diagnosed cancer in women in the US.
  • Breast cancer deaths in 2021 are estimated at 44,130 (43,600 women, 530 men), making breast cancer the 2nd leading cause of cancer death in women (after lung cancer).
  • As reported by the American Cancer Society in 2021, approximately 62% of breast cancer is detected in early stages (i.e., the cancer is found in the breast tissue, and has not spread to lymph nodes or other regions of the body), for which the 5-year survival rate is estimated at 99%. As soon as the cancer spreads to lymph nodes under the arm or nearby tissues (regional stage), the 5-year survival rate drops to 85%. However, once the cancer spreads to other lymph nodes or body parts {distant stage or metastatic (met-uh-STAT-ic) cancer}, the five-year survival rate falls to as low as 27% (i.e. 73% of the patients die within 5 years). This shows the grave need for effective treatments for this deadly cancer.